Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial
V. Lorenzetti, E. McTavish, S. Broyd, H. van Hell, Eleni P. Ganella, A. Kottaram, Camilla Beale, Jennifer H. Martin, P. Galettis, N. Solowij, L. Greenwood
Cannabis and Cannabinoid Research July 26, 2023 DOI: 10.1089/can.2022.0336 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label pragmatic trial Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Sample size | 18 |
| Population | People who use cannabis |
| Intervention | Cannabidiol (CBD) |
| Dose | 200 mg daily |
| Duration | Approximately 10 weeks |
| Topics | Cannabis CBD |
| Key findings | About 10 weeks of daily 200 mg CBD was associated with decreased anterior hippocampus-precentral gyrus connectivity (d=1.73) and increased amygdala-lingual gyrus connectivity (d=1.19) in cannabis users. No associations were found with cannabinoid exposure or mental health symptom scores. The authors propose CBD may restore or reduce connectivity differences reported in cannabis users, but call for double-blind, placebo-controlled replication. |
Abstract
Introduction: Cannabis use is associated with brain functional changes in regions implicated in prominent neuroscientific theories of addiction. Emerging evidence suggests that cannabidiol (CBD) is neuroprotective and may reverse structural brain changes associated with prolonged heavy cannabis use. In this study, we examine how an ∼10-week exposure of CBD in cannabis users affected resting-state functional connectivity in brain regions functionally altered by cannabis use.
Materials and Methods: Eighteen people who use cannabis took part in a ∼10 weeks open-label pragmatic trial of self-administered daily 200 mg CBD in capsules. They were not required to change their cannabis exposure patterns. Participants were assessed at baseline and post-CBD exposure with structural magnetic resonance imaging (MRI) and a functional MRI resting-state task (eyes closed). Seed-based connectivity analyses were run to examine changes in the functional connectivity of a priori regions—the hippocampus and the amygdala. We explored if connectivity changes were associated with cannabinoid exposure (i.e., cumulative cannabis dosage over trial, and plasma CBD concentrations and Δ9-tetrahydrocannabinol (THC) plasma metabolites postexposure), and mental health (i.e., severity of anxiety, depression, and positive psychotic symptom scores), accounting for cigarette exposure in the past month, alcohol standard drinks in the past month and cumulative CBD dose during the trial.
Results: Functional connectivity significantly decreased pre-to-post the CBD trial between the anterior hippocampus and precentral gyrus, with a strong effect size (d=1.73). Functional connectivity increased between the amygdala and the lingual gyrus pre-to-post the CBD trial, with a strong effect size (d=1.19). There were no correlations with cannabinoids or mental health symptom scores.
Discussion: Prolonged CBD exposure may restore/reduce functional connectivity differences reported in cannabis users. These new findings warrant replication in a larger sample, using robust methodologies—double-blind and placebo-controlled—and in the most vulnerable people who use cannabis, including those with more severe forms of Cannabis Use Disorder and experiencing worse mental health outcomes (e.g., psychosis, depression).
Comparable studies
Other non-randomized and open-label trials on CBD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. Individuals diagnosed with long COVID | 2024 | Single-arm open-label feasibility trial | n = 12 |
| Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program. Association workers and young people in France | 2024 | Pre-post intervention evaluation | n = 666 |